1 / 4

Roche’s Small Deal Has Big Cancer Promise

(Bloomberg Opinion) — When it comes to this month’s dealmaking in biotech, the record $74 billion takeover of Celgene Inc. by Bristol-Myers Squibb & Co. has been the focus of attention. A smaller transaction that came around the same time deserves more notice than it got.

The deal, announced on Jan. 4, is a licensing agreement reached between Roche Holding AG’s Genentech unit and closely held Adaptive Biotechnologies, and it’s potentially worth more than $2.3 billion before

Read More At Article Source | Article Attribution